

PHARMA MEMBER COMPANIES RAISE CONCERNS WITH IMPACT OF PROPOSED INTERNATIONAL PRICING INDEX MODEL

One of the biggest myths regarding the proposed International Pricing Index Model is that it will have little to no effect on biomedical research and development (R&D). In fact, a recent survey of PhRMA member companies found many expect the proposal to greatly affect their R&D. Here are some of the key findings from survey respondents:

77%

of companies said that if the proposal goes through, it will affect their ability to pursue **current or future** R&D projects.



92%

of companies saw a **risk of reducing investments in all Part B medicines**, which are primarily biologics that are administered by physicians and used to treat many diseases like multiple sclerosis, rheumatoid arthritis, cancer and genetic disorders.



88%

of companies said **cell and gene therapy** projects could be affected.



70%

of companies expected significant cuts in **cancer** R&D.



HALF

of the companies reported that **20% or more** of their current projects could be **reduced or terminated**.



66%

of companies expressed concern about near-term **job cuts**, the **eventual closure** of facilities or **abandonment** of expansion plans.



Learn more at PhRMA.org/PartB

Source: Survey commissioned by PhRMA and conducted in December 2018 by the law firm of Manatt, Phelps & Phillips, LLP.

PhRMA
RESEARCH • PROGRESS • HOPE